3 results
Compare Progression Free Survival (PFS) for brivanib versus placebo in subjects with advanced solid tumors with FGF-2 over-expression and who have obtained stable disease after 12 weeks of treatment with brivanib separately for each tumor.
The purpose of this study is to investigate the effects of the new compound efgartigimod on IgG antibodies. It will also be investigated how quickly and to what extent efgartigimod given together with rHuPH20, is absorbed and eliminated from the…
Primary objectives: The main objective of this Post Market Clinical Follow-Up (PMCF) study is to further evaluate and monitor the safety and performance of the *BasIQ-4®* in a population of women delivering in general hospitals in The Netherlands…